Tempus AI

Tempus AI Net Change in Cash

The Net Change in Cash of Tempus AI (TEM) as of Nov 20, 2026 is 267.62 M USD. In the previous year, Net Change in Cash was 175.23 M USD — a change of 52.72% (higher).

Net Change in Cash

267.62 MUSD

YoY

52.72%

Last updated:

Net Change in Cash of Tempus AI is 2025 267.62 M USD. Net Change in Cash of Tempus AI was 2024 175.23 M USD. It decreases by 52.72% higher compared to the previous year.

The Tempus AI Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
36.54 M USD
Jan 1, 2020
286.12 M USD
Jan 1, 2021
-235.75 M USD
Jan 1, 2022
25.27 M USD
Jan 1, 2023
-137.12 M USD
Jan 1, 2024
175.23 M USD
Jan 1, 2025
267.62 M USD
The Tempus AI Net Change in Cash history
YEARNet Change in CashYoY
267.62 MUSD+52.72%
175.23 MUSD-227.79%
-137.12 MUSD-642.74%
25.27 MUSD-110.72%
-235.75 MUSD-182.40%
286.12 MUSD+682.94%
36.54 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Net Change in Cash of Tempus AI is 267.62 M USD in 2025.

Net Change in Cash of Tempus AI changed from 175.23 M USD to 267.62 M USD, representing a 52.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI